SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-23-141993
Filing Date
2023-05-11
Accepted
2023-05-11 16:01:22
Documents
58
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d246051d10q.htm   iXBRL 10-Q 1103033
2 EX-31.1 d246051dex311.htm EX-31.1 6579
3 EX-31.2 d246051dex312.htm EX-31.2 6570
4 EX-32.1 d246051dex321.htm EX-32.1 3142
5 EX-32.2 d246051dex322.htm EX-32.2 3133
  Complete submission text file 0001193125-23-141993.txt   4840525

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vinc-20230331.xsd EX-101.SCH 30381
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vinc-20230331_cal.xml EX-101.CAL 27731
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vinc-20230331_def.xml EX-101.DEF 182168
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20230331_lab.xml EX-101.LAB 309713
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20230331_pre.xml EX-101.PRE 261308
52 EXTRACTED XBRL INSTANCE DOCUMENT d246051d10q_htm.xml XML 730517
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

IRS No.: 833197402 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39244 | Film No.: 23910767
SIC: 2834 Pharmaceutical Preparations